Proteome Sciences driven by strong sales and the associated royalties

Jeremy Haigh, Chief Executive of Proteome Sciences LON:PRM, commented: “While progress was slower than we would have wished during 2017, particularly on the services side of the business where early adoption has been challenging, this is not surprising given the scale of change undertaken by the Company in the first half of the year. However, with the benefits of a leaner organisation, a new model for commercial engagement now fully deployed in both our principal operating territories and the reassurance of robust and increasing demand for our TMT(R) reagents, we have the platform necessary to realise the full value of our available proteomic technologies. Following fundamental changes to our services business we are encouraged by stronger performance in the fourth quarter of 2017 and the order book moving into 2018. It is now possible to consider the range of options available to a company with our ambition; I look forward to doing this and to providing further updates throughout the course of the year.”

 

Driven by strong sales of our TMT(R) reagents and the associated royalties, unaudited revenues for the full year increased by 18% to approximately GBP3.2m (2016: GBP2.7m). Costs of GBP5.1m were 5% lower than the previous year (2016: GBP5.4m) reflecting the early impact of consolidation and restructuring. The Company anticipates a reduced loss before tax of approximately GBP2.1m (2016: GBP2.9m).

While there has been significant volatility in foreign exchanges during the course of the year, affecting non-sterling denominated revenues as well as those costs associated with our primary facility in Frankfurt, the overall effect on EBITDA was neutral.

Cash reserves at the year-end were approximately GBP0.8m despite the delayed payment of a material 2016 R&D tax credit, receipt of which is now expected during the first quarter of 2018. In addition, the Board is pleased with a strengthening order book carried through from late 2017.

The Directors look forward to updating shareholders further on the Company’s performance, and on the outlook for 2018, at the time of the full year results.

Appointment of Sales Agent in Europe

A sales agent model has now been introduced in Europe, similar to that initiated in the US last summer. Cenibra GmbH signed a contract covering German speaking countries and, following training in January, has agreed a selling plan for immediate implementation. We are confident that this engagement will quickly increase our access to a broader client base in Europe and complete the fundamental change necessary for the commercialisation of our services business.

 

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Proteome Sciences Plc

    More articles like this

    Proteome Sciences Plc

    Proteome Sciences plc Board Appointment

    Proteome Sciences plc (LON:PRM) has today announced that Mr Richard Dennis has today been appointed to the Board of Directors.  As communicated on 3 April 2017, when he joined the Company as its first Chief Commercial

    Proteome Sciences Plc

    Proteome Sciences plc License Agreement Extension

    Electrophoretics Ltd, a wholly owned subsidiary of Proteome Sciences plc (LON:PRM), is pleased to announce that it has signed an amendment to the exclusive License and Distribution Agreement with Pierce Biotechnology Inc., a part of Thermo Fisher

    Proteome Sciences Plc

    Proteome Sciences plc Notice of Results

    The Directors look forward to updating shareholders on the Company’s performance, and on the outlook for 2018, at the time they announce their 2017 full year results which are scheduled for release on 24 April 2018. 

    Proteome Sciences Plc

    Proteome Sciences plc accreditation for clinical stage contracts

    Proteome Sciences plc has this morning announced the receipt of Good Clinical Laboratory Practice (GCLP) accreditation which will now enable it to compete effectively for clinical stage contracts commanding routinely larger budgets; the benefits of this

    Proteome Sciences Plc

    Proteome Sciences sales and royalties have increased 40%

    Proteome Sciences LON:PRM has given DirectorsTalk its unaudited interim results for the six months ended 30 June 2017. Financial highlights: — Total revenues increased 21% to GBP1.36m (2016: GBP1.12m) — TMT(R) reagent sales and royalties increased